• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lots of long COVID treatment leads, but few are proven.

作者信息

Shaffer Leah

出版信息

Proc Natl Acad Sci U S A. 2022 Sep 6;119(36):e2213524119. doi: 10.1073/pnas.2213524119. Epub 2022 Sep 1.

DOI:10.1073/pnas.2213524119
PMID:36048910
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9456722/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d53/9456722/a51063dd601c/pnas.2213524119fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d53/9456722/c6e111ce8e10/pnas.2213524119fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d53/9456722/a51063dd601c/pnas.2213524119fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d53/9456722/c6e111ce8e10/pnas.2213524119fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d53/9456722/a51063dd601c/pnas.2213524119fig02.jpg

相似文献

1
Lots of long COVID treatment leads, but few are proven.治疗长期新冠有很多线索，但经证实的却很少。
Proc Natl Acad Sci U S A. 2022 Sep 6;119(36):e2213524119. doi: 10.1073/pnas.2213524119. Epub 2022 Sep 1.
2
COVID-19 long haulers.新冠长期症状患者。
Nat Biotechnol. 2021 Aug;39(8):908-913. doi: 10.1038/s41587-021-00984-7.
3
Sulodexide: A Benefit for Cardiovascular Sequelae of Long COVID Patients?舒洛地昔：对新冠长期症状患者的心血管后遗症有益？
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221084300. doi: 10.1177/10760296221084300.
4
Long-COVID treatments: why the world is still waiting.长期新冠的治疗方法：为何全球仍在等待。
Nature. 2022 Aug;608(7922):258-260. doi: 10.1038/d41586-022-02140-w.
5
Can drugs reduce the risk of long COVID? What scientists know so far.药物能降低长期新冠的风险吗？科学家目前所了解的情况。
Nature. 2022 Apr;604(7904):20-21. doi: 10.1038/d41586-022-00823-y.
6
Private venture tackles Long Covid, aims to test drugs soon.私人风险投资公司涉足长新冠领域，旨在尽快进行药物测试。
Science. 2022 Sep 16;377(6612):1245. doi: 10.1126/science.ade8709. Epub 2022 Sep 15.
7
Intravenous immunoglobulin: A potential treatment for the post-acute sequelae of SARS-Cov-2 infection?静脉注射免疫球蛋白：一种治疗新冠病毒感染后急性后遗症的潜在疗法？
Bosn J Basic Med Sci. 2022 Jul 29;22(4):660-664. doi: 10.17305/bjbms.2021.6901.
8
Oral antivirals for acute symptoms and post-acute sequelae in SARS-CoV-2 infection.用于治疗新型冠状病毒感染急性症状和急性后遗症的口服抗病毒药物。
Lancet Infect Dis. 2024 Oct;24(10):1066-1067. doi: 10.1016/S1473-3099(24)00258-5. Epub 2024 May 3.
9
Trials Will Evaluate Treatments for Long COVID Nervous System Problems.试验将评估针对新冠长期症状神经系统问题的治疗方法。
JAMA. 2024 May 7;331(17):1439-1440. doi: 10.1001/jama.2024.5156.
10
Therapeutic and prophylactic effect of flavonoids in post-COVID-19 therapy.COVID-19 后治疗中类黄酮的治疗和预防作用。
Phytother Res. 2022 May;36(5):2042-2060. doi: 10.1002/ptr.7436. Epub 2022 Mar 18.

引用本文的文献

1
The Challenge of Long COVID: Is the Pandemic Really Over?长新冠的挑战：疫情真的结束了吗？
Public Health Rep. 2025 Aug 17:333549251358665. doi: 10.1177/00333549251358665.
2
Sociodemographic factors, biomarkers and comorbidities associated with post-acute COVID-19 sequelae in UK Biobank.英国生物银行中与急性后新冠后遗症相关的社会人口学因素、生物标志物和合并症
Nat Commun. 2025 Jul 30;16(1):7009. doi: 10.1038/s41467-025-62354-0.
3
Mechanisms of long COVID: An updated review.长新冠的发病机制：最新综述

本文引用的文献

1
Famotidine activates the vagus nerve inflammatory reflex to attenuate cytokine storm.法莫替丁通过激活迷走神经炎症反射减轻细胞因子风暴。
Mol Med. 2022 May 16;28(1):57. doi: 10.1186/s10020-022-00483-8.
2
Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study.COVID-19 住院幸存者 2 年后的健康结局：一项纵向队列研究。
Lancet Respir Med. 2022 Sep;10(9):863-876. doi: 10.1016/S2213-2600(22)00126-6. Epub 2022 May 11.
3
Non-invasive Vagus Nerve Stimulation for COVID-19: Results From a Randomized Controlled Trial (SAVIOR I).
Chin Med J Pulm Crit Care Med. 2023 Dec 6;1(4):231-240. doi: 10.1016/j.pccm.2023.10.003. eCollection 2023 Dec.
4
Modifiable lifestyle factors and the risk of post-COVID-19 multisystem sequelae, hospitalization, and death.可改变的生活方式因素与 COVID-19 后多系统后遗症、住院和死亡的风险。
Nat Commun. 2024 Jul 29;15(1):6363. doi: 10.1038/s41467-024-50495-7.
5
Type I interferon pathway genetic variants in severe COVID-19.严重 COVID-19 中 I 型干扰素通路遗传变异。
Virus Res. 2024 Apr;342:199339. doi: 10.1016/j.virusres.2024.199339. Epub 2024 Feb 22.
6
The importance of patient-partnered research in addressing long COVID: Takeaways for biomedical research study design from the RECOVER Initiative's Mechanistic Pathways taskforce.在解决长新冠问题中重视患者参与式研究：从 RECOVER 倡议的机制途径工作组中为生物医学研究设计获得的经验教训。
Elife. 2023 Sep 22;12:e86043. doi: 10.7554/eLife.86043.
7
Melatonin, vitamins and minerals supplements for the treatment of Covid-19 and Covid-like illness: A prospective, randomized, double-blind multicenter study.褪黑素、维生素和矿物质补充剂治疗 COVID-19 和类 COVID 疾病：一项前瞻性、随机、双盲、多中心研究。
Explore (NY). 2024 Jan-Feb;20(1):95-100. doi: 10.1016/j.explore.2023.06.009. Epub 2023 Jun 20.
8
Long COVID: Costs for the German economy and health care and pension system.长新冠：对德国经济以及医保和养老金体系的影响。
BMC Health Serv Res. 2023 Jun 14;23(1):641. doi: 10.1186/s12913-023-09601-6.
9
Corona With Lyme: A Long COVID Case Study.新冠与莱姆病：一例长期新冠病例研究。
Cureus. 2023 Mar 24;15(3):e36624. doi: 10.7759/cureus.36624. eCollection 2023 Mar.
10
A review of cytokine-based pathophysiology of Long COVID symptoms.基于细胞因子的长新冠症状病理生理学综述。
Front Med (Lausanne). 2023 Mar 31;10:1011936. doi: 10.3389/fmed.2023.1011936. eCollection 2023.
用于治疗 COVID-19 的非侵入性迷走神经刺激：一项随机对照试验（SAVIOR I）的结果
Front Neurol. 2022 Apr 8;13:820864. doi: 10.3389/fneur.2022.820864. eCollection 2022.
4
Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection.胃肠道症状和 SARS-CoV-2 RNA 的粪便脱落表明胃肠道感染时间延长。
Med. 2022 Jun 10;3(6):371-387.e9. doi: 10.1016/j.medj.2022.04.001. Epub 2022 Apr 13.
5
Factors Associated with Post-Acute Sequelae of SARS-CoV-2 (PASC) After Diagnosis of Symptomatic COVID-19 in the Inpatient and Outpatient Setting in a Diverse Cohort.与 SARS-CoV-2（PASC）在门诊和住院环境中诊断为有症状的 COVID-19 后出现的急性后遗症相关的因素。
J Gen Intern Med. 2022 Jun;37(8):1988-1995. doi: 10.1007/s11606-022-07523-3. Epub 2022 Apr 7.
6
Multiorgan and Vascular Tropism of SARS-CoV-2.SARS-CoV-2 的多器官和血管嗜性。
Viruses. 2022 Mar 3;14(3):515. doi: 10.3390/v14030515.
7
The immunology and immunopathology of COVID-19.新型冠状病毒肺炎的免疫学和免疫病理学。
Science. 2022 Mar 11;375(6585):1122-1127. doi: 10.1126/science.abm8108. Epub 2022 Mar 10.
8
The Role of Lipopolysaccharide-Induced Cell Signalling in Chronic Inflammation.脂多糖诱导的细胞信号传导在慢性炎症中的作用
Chronic Stress (Thousand Oaks). 2022 Feb 8;6:24705470221076390. doi: 10.1177/24705470221076390. eCollection 2022 Jan-Dec.
9
Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial.口服法莫替丁与安慰剂治疗非住院 COVID-19 患者的随机、双盲、数据密集型、2 期临床试验。
Gut. 2022 May;71(5):879-888. doi: 10.1136/gutjnl-2022-326952. Epub 2022 Feb 10.
10
Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection.新冠病毒感染后 15 个月，COVID-19 后急性后遗症（PASC）中 CD16+ 单核细胞中 SARS-CoV-2 S1 蛋白持续存在。
Front Immunol. 2022 Jan 10;12:746021. doi: 10.3389/fimmu.2021.746021. eCollection 2021.